EP1541675A3 - Hybrid cells obtainable from antigen presenting cells - Google Patents

Hybrid cells obtainable from antigen presenting cells Download PDF

Info

Publication number
EP1541675A3
EP1541675A3 EP05005671A EP05005671A EP1541675A3 EP 1541675 A3 EP1541675 A3 EP 1541675A3 EP 05005671 A EP05005671 A EP 05005671A EP 05005671 A EP05005671 A EP 05005671A EP 1541675 A3 EP1541675 A3 EP 1541675A3
Authority
EP
European Patent Office
Prior art keywords
cells
hybrid
antigen presenting
obtainable
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05005671A
Other languages
German (de)
French (fr)
Other versions
EP1541675A2 (en
Inventor
Thomas Wagner
Yanzhang Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orbis Health Solutions LLC
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Priority claimed from EP01908591A external-priority patent/EP1248836B1/en
Publication of EP1541675A2 publication Critical patent/EP1541675A2/en
Publication of EP1541675A3 publication Critical patent/EP1541675A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system. For instance, dendritomas produced by fusing dendritic cells with cancer cells may be used as a cellular vaccine.
EP05005671A 2000-01-11 2001-01-09 Hybrid cells obtainable from antigen presenting cells Ceased EP1541675A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17537600P 2000-01-11 2000-01-11
US175376P 2000-01-11
EP01908591A EP1248836B1 (en) 2000-01-11 2001-01-09 Method for preparing vaccines by using hybrid cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP01908591A Division EP1248836B1 (en) 2000-01-11 2001-01-09 Method for preparing vaccines by using hybrid cells

Publications (2)

Publication Number Publication Date
EP1541675A2 EP1541675A2 (en) 2005-06-15
EP1541675A3 true EP1541675A3 (en) 2007-08-08

Family

ID=34524430

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05005671A Ceased EP1541675A3 (en) 2000-01-11 2001-01-09 Hybrid cells obtainable from antigen presenting cells

Country Status (1)

Country Link
EP (1) EP1541675A3 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003576A1 (en) * 1988-09-27 1990-04-05 Cetus Corporation Cell sorting technique and applications thereof
WO1996030030A1 (en) * 1995-03-31 1996-10-03 Universite Libre De Bruxelles Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003576A1 (en) * 1988-09-27 1990-04-05 Cetus Corporation Cell sorting technique and applications thereof
WO1996030030A1 (en) * 1995-03-31 1996-10-03 Universite Libre De Bruxelles Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELLUZZI C M ET AL: "Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 APR 1998, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3081 - 3085, XP002167051, ISSN: 0022-1767 *
HOLMES L M ET AL: "A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphoctye responses using instant dentritomas.", JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) 2001 MAR-APR, vol. 24, no. 2, March 2001 (2001-03-01), pages 122 - 129, XP008079909, ISSN: 1524-9557 *
LI J ET AL: "Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII NOV 2001, vol. 50, no. 9, November 2001 (2001-11-01), pages 456 - 462, XP002437116, ISSN: 0340-7004 *
SCHAAP G H ET AL: "GENE EXPRESSION IN FLOW SORTED MOUSE TERATO CARCINOMA X HUMAN FIBROBLAST HETEROKARYONS", DIFFERENTIATION, vol. 26, no. 2, 1984, pages 127 - 133, XP001010038, ISSN: 0301-4681 *
TREFZER U ET AL: "A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1998, vol. 451, 1998, pages 519 - 525, XP002987126, ISSN: 0065-2598 *

Also Published As

Publication number Publication date
EP1541675A2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CA2259140A1 (en) Method of activating dendritic cells
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2003020884A3 (en) Method for rapid generation of mature dendritic cells
EP2298927A3 (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2003040340A3 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2003024480A3 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
WO2000054802A3 (en) Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
EP2583981A3 (en) Antibodies and related molecules that bind to PSCA proteins
WO2005037223A3 (en) Methods and compositions for immunomodulation
AU2002221033A1 (en) Cells to be used in producing virus vector, process for producing the same and process for producing virus vector with the use of the cells
WO2003050255A3 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
NZ514230A (en) A single step method for lysing cells and cleaving a fusion protein
WO2001051608A3 (en) Hybrid cells obtainable from antigen presenting cells
WO2002072785A3 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
AU2667995A (en) Chimerical peptide-nucleic acid fragment, process for producing the same and its use for appropriately introducing nucleic acids into cell organelles and cells
WO2002007752A3 (en) Red blood cell as vehicle for agent-membrane translocation sequence conjugate
EP1541675A3 (en) Hybrid cells obtainable from antigen presenting cells
WO2002060953A3 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
WO2002083919A3 (en) Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1248836

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/04 20060101ALI20070626BHEP

Ipc: C12N 5/22 20060101ALI20070626BHEP

Ipc: A61P 35/00 20060101ALI20070626BHEP

Ipc: A61P 37/00 20060101ALI20070626BHEP

Ipc: C12N 5/24 20060101ALI20070626BHEP

Ipc: A61K 39/00 20060101ALI20070626BHEP

Ipc: A61K 38/20 20060101ALN20070626BHEP

Ipc: A61K 35/14 20060101ALI20070626BHEP

Ipc: C12N 5/12 20060101AFI20070626BHEP

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GHC RESEARCH DEVELOPMENT CORPORATION

17P Request for examination filed

Effective date: 20080201

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20090224

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WAGNER, THOMAS E.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WAGNER, THOMAS E.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ORBIS HEALTH SOLUTIONS LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150922